)

Caitlyn Krebs
Caitlyn is a biotech entrepreneur and the Co-Founder & CEO of Nalu Bio, leading a team of innovators harnessing AI and the endocannabinoid system (ECS) to tackle modern health challenges. Nalu Bio’s proprietary AI platform designs novel, highly effective, and safe small molecules targeting pain, weight management, stress, sleep, and mobility—advancing healthcare solutions without the side effects of traditional treatments.
With 20+ years of experience at the intersection of science, technology, and commercialization, Caitlyn has built and led companies pioneering ML & AI-driven drug discovery (Entelos), diabetes prevention (Tethys), Alzheimer’s prevention (Neurotrack), and early cancer detection (Bluestar Genomics). She has held leadership roles in management, operations, sales, and corporate development—driving go-to-market strategies and scaling adoption of breakthrough innovations.
Passionate about solving large-scale healthcare challenges, Caitlyn is now focused on unlocking the therapeutic potential of the endocannabinoid system.